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S106Bronchiolitis Obliterans Syndrome After Allogeneic
Hematopoietic Stem Cell Transplantation—An
Increasingly Recognized Manifestation of Chronic
Graft-versus-Host Disease
Jason W. Chien,1 Steven Duncan,2 Kirsten M. Williams,3 Steven Z. Pavletic3Bronchiolitis obliterans syndrome (BOS) is a progressive, insidious, and often fatal lung alloreaction that can
occur following allogeneic hematopoietic stem cell transplantation (HSCT) or allogeneic lung transplanta-
tion. Current estimates in the literature suggest that approximately 2% to 3% of all allogeneic HSCTrecip-
ients and 6% of patients who develop chronic graft-versus-host disease (cGVHD) will develop this syndrome.
However, based on newer data it is likely that the true incidence of BOS is higher. Unfortunately, the survival
and treatment of patients with BOS after HSCT has not improved over the last 20 years. Attempts at clinical
trials have been hindered by the lack of uniform diagnostic criteria and inability to detect the syndrome at
a reversible stage in its natural history. Recently, the National Institutes of Health (NIH) consensus project
for criteria in cGVHD has made recommendations regarding the diagnosis of BOS and monitoring of lung
disease among long-term survivors. Although a rare and poorly understood manifestation of cGVHD,
BOS occurs commonly after lung transplantation and is similar in pathology, clinical presentation,
radiographic presentation, and presumed immunologic pathogenesis. This review describes the current
understanding of the epidemiology and pathogenesis of BOS and presents information on evaluations and
therapies for patients with BOS after HSCT.
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The significant decrease in early treatment-related
mortality (TRM) after allogeneic hematopoietic cell
transplantation (HSCT) increased the number of pa-
tients living long enough to experience late complica-
tions of transplantation. Chronic graft-versus-host
disease (cGVHD) is the most common late complica-
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ensues. Unfortunately, the survival and treatment of
patients with BOS have not improved over the last
20 years [1,2]. Attempts at clinical trials have been
hindered by the lack of uniform diagnostic criteria.
Recently, the NIH consensus project for criteria in
cGVHDhasmade recommendations regarding the di-
agnosis of BO and monitoring of lung disease among
long-term survivors [3]. Challenges to the progress
in medical management of BOS include little knowl-
edge about pathogenesis to direct effective therapies
and delay in diagnosis. This article provides an over-
view of the epidemiology, diagnosis, and treatment
of BOS and the immunobiology of BOS after lung
transplantation, a better understood disease similar
to BOS after HSCT pathologically, clinically, and
radiographically.EPIDEMIOLOGYAND PATHOGENESIS OF
BRONCHOLITIS OBLITERANS AFTER
ALLOGENEIC HSCT
BOS is a rare complication of allogeneic HSCT,
characterized by the new development of fixed airflow
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the definition used to define BOS, the prevalence of
this syndrome ranges from approximately 2% to 3%
among all allogeneic HCT recipients to 6% of patients
who develop cGVHD [1,4-6]. Studies that have used
more relaxed definitions have suggested that the prev-
alence may be even higher. We hypothesized that be-
cause this syndrome is characterized by airflow
obstruction, early rapid airflow decline, defined as an
annualized rate of 1-second forced expiratory volume
(FEV1) decline of 5% per year, might identify a popu-
lation at higher risk for poor outcomes [7]. This study
revealed that among all patients who receive an alloge-
neic transplant, 26% developed significant airflow de-
cline, and among patients who developed cGVHD,
30% had significant airflow decline after transplant.
Rapid airflow decline was also associated with signifi-
cant attributable mortality rates of 9% at 3 years,
12% at 5 years, and 18% at 10 years after transplant.
Mortality was much higher for the subpopulation of
patients with cGVHD (22% at 3 years, 27% at 5 years,
and 40% at 10 years) [7]. These results suggested that
the prevalence of airflow obstruction after allogeneic
HSCT may have been underestimated previously,
and the presence of rapid early airflow decline within
the first year after transplant is associated with signifi-
cantly increased risk for mortality even among long-
term survivors. As an effort to provide a uniformed def-
inition of BOS for clinical management and clinical
trials, the NIH recently provided new guidelines for
the diagnosis of nonpathologically confirmed BOS
(see later) [3]. Using this stringent definition, we con-
ducted an analysis that revealed an overall BOS preva-
lence of approximately 5.5%, with 10% in patients
surviving at least 1 year after transplant and 16% of
all patients with cGVHD (Jason Chien, personal com-
munication). Again, these data suggest that BOS is
likely under recognized in the transplant community.
Many risk factors have been found to be associated
with the development of BOS after allogeneic HSCT.
These include low IgG levels, the use of peripheral
blood stem cells (PBSCs), the use of busulfan (Bu) or
methotrexate (MTX) during the transplant process,
the intensity of the conditioning employed, and poor
pretransplant lung function and respiratory infection
during the first 100 days post transplantation [4,6-
10]. The clinical factor most commonly associated
with the development of BOS is the presence of
GVHD at another site [11-16]. In a study by Dudek
et al. [1], 81% of all of the BOS cases was diagnosed
with GVHD prior to the onset of BOS. Even in our
study assessing a milder definition of airflow obsruc-
tion, all of the patients who had significant early air-
flow decline had some form of GVHD at a site other
than the lung [7]. In the same study, older age at trans-
plant, poor lung function at baseline, and respiratory
viral infection within the first 100 days aftertransplant were also identified as risk factors for early
airflow decline. Additional analysis of the early respira-
tory viral infections revealed that most respiratory viral
infections during the first 100 days after HCT result in
fixed airflow obstruction at 1 year and lower respira-
tory tract parainfluenza virus infection was associated
with the highest risk for fixed airflow obstruction at
1 year (odds ratio, 17.9 [95% confidence interval
(CI), 2.0-160]; P 5 .01) [17].
Examination or pathologic samples have contrib-
uted to our understanding of BOS. Biopsy specimens
usually demonstrate bronchiolitis involving the small
airways and fibrinous obliteration of the lumen of the
respiratory bronchioles, with or without associated
interstitial pneumonia, fibrosis, or diffuse alveolar
damage; inflammatory cell infiltrates consisting of
neutrophils and mononuclear cells (MNCs), the for-
mer more often in the lumens of the affected bronchi-
oles, are prominent early in the disease process [18,19].
In the chronic phase, there are variable degrees of in-
tralumenal or peribronchiolar fibrosis, ranging from
proliferation of fibroblasts andmyofibroblasts to colla-
gen scarring. This leads to progressive circumferential
fibrosis and ultimate cicatrization of the small terminal
airways, manifesting as new fixed airflow obstruction.
Despite all the advances in stem cell transplantation
(SCT) over the last 2 decades, the cause of BOS is still
unknown. Allorecognition of lung antigens is the sus-
pected etiology of this disease because the 2 clinical sit-
uations associatedwithBOS involve alloimmunity, lung
transplantation—host (hematopoietic cells)-versus-
graft (lung) disease, and HCT—graft (hematopoietic
cells)-versus-host (lung) disease. Additionally, when
BOS occurs after HCT, it is typically accompanied by
alloimmune manifestations in other organs, for exam-
ple, liver, eyes, or skin. Indeed, the lung epithelium
may be the target of immune mediated-injury induced
by donor cytotoxic T cells in cGVHD [6], supporting
the hypothesis that BOS is a manifestation of cGVHD
in the lung. Unfortunately, there are no direct data to
support this statistical correlation; animal models of
graft-versus-host (GVH) reactions in the lungs primar-
ily result in alveolitis and interstitial infiltration with
lymphocytes and associated chemokines and cytokines
such as tumor necrosis factor (TNF) alpha. Unfortu-
nately, all of these studies have been conducted using
mouse models of host versus graft disease, which is
more representative of lung transplantation [18,20-24].
There is also substantial evidence from studies in
other airway diseases associatedwith chronic airway in-
flammation that endotoxin-induced cellular activation
and other components of the innate immune system
may play an important role in the pathogenesis, and
that the innate immune response is likely under genetic
control [25-28]. To test the hypothesis in the BOS set-
ting, we preformed a study using a gene-wide approach
to determine if genetic variation in the innate immune
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following HCT [29]. Single marker tagSNP analysis
of 15 genes in the innate immunity pathway demon-
strated significant associations with the patients BPI
genotype for rs 33065, P 5 .038; and rs 36045, P 5
.025. Multimarker haplotype analysis of the BPI
tagSNPs demonstrated that 4 haplotypes in the patient
and donor samples were significantly associated with
a 2- to 3-fold increase in risk for developing airflow
decline (P-values .004 to .038). In a validation study
carried out in an independent cohort of patients, an
association with 9 haplotypes in the BPI gene was de-
tected (P-values .013 to .043), suggesting that genetic
variants on the BPI gene or in linkage disequilibrium
with the BPI tagSNP haplotypes identified may influ-
ence the risk for developing HSCT-related AFO. Hil-
debrant et al. [30] conducted an analysis of theNOD2/
CARD15 variants (SNP8 [Arg702Trp], SNP12
[Gly908Arg], and SNP13 [Leu1007fsinsC]), and found
that the cumulative incidence of BO rose from 1.3% in
donor-recipient pairs without mutation to 18.7% in
pairs with donor or recipient NOD2/CARD15 vari-
ants (P \ .001), and the recipient NOD2/CARD15
variants alone led to BO in 22.3% (P\ .001), whereas
donor variants alone associated with BO in 13.2% (P5
.04). Similar studies in lung transplantation have also
found genetic associations between CD14 variants
and lung transplant outcomes [31].BOS IN LUNG ALLOGRAFT RECIPIENTS
BOS that occurs after allogeneic lung transplanta-
tion shares a number of common features with the
BOS of allogeneic HSCT recipients. The histologic
features and clinicalmanifestations of BOS are virtually
indistinguishable among these transplantation popula-
tions. In the case of pulmonary transplantation, experi-
mental evidence affirms BOS is a sequela of recipient
(host) adaptive immune processes that are triggered
by T cells with reactivity for allogeneic donor lung
(graft) epitopes [32-36]. BOS among HSCT recipients
results from grafted (donor) hematologic cell responses
that target allogeneic lung epitopes (in addition to other
organs) of the hosts (recipients) [37]. Thus, the immu-
nopathogenesis of BOS in lung transplant patients is
a ‘‘mirror image’’ of the abnormality among HSCT
recipients. The requisite feature of both cases is the
presence of immune effector cells, particularly T cells,
which mount chronic rejection responses against lung
alloantigens. As such, insights relevant to the pathogen-
esis of BOS in either transplant population could have
useful application in the other patient group.
BOS eventually occurs in.50% of long-surviving
lung transplant recipients [38], and thus is far more
prevalent than after HSCT. The increased BOS fre-
quency of lung transplantation is probably a reflectionof greater donor:recipient alloantigen disparities. Un-
like HCT, lung allografts are only rarely and fortu-
itously HLA matched with recipients, because the
logistics of these donor organ procurements are so
problematic. BOS is overwhelmingly the single most
frequent serious complication of lung transplantation,
and the prevalence of this complication has not appre-
ciably diminished for more than 2 decades [38,39].
Contributing Factors for the Development of
BOS
Multiple factors are known to increase risks for
BOS after lung transplantation. The number of HLA
donor:recipient mismatches are correlated with
increased incidences of BOS [40]. Acute rejection (ie,
lymphocytic infiltrations) is near ubiquitous in trans-
plant recipients, and the severity and number of these
episodes are also correlated with risks for later BOS
[41,42]. Anti-allo-HLA IgG antibodies are produced
among many (albeit not all) lung transplant recipients,
and the presence and quantity of these immunoglobu-
lins are also associated with development of BOS [43].
However, the specific contribution of these humoral
responses to BOS pathogenesis is uncertain, given
that analogous chronic rejection injuries also occur
among B cell knock-out animals.
BOS is also more frequent among lung transplant
recipients who had ischemia-reperfusion injuries of
the newly implanted donor lung [44], developed pul-
monary infections, particularly with cytomegalovirus
(CMV) [45], or have certain other comorbidities,
including gastroesophageal reflux disease (GERD)
[40]. Although often described as ‘‘allo-independent’’
factors, these comorbidities almost certainly exert
their deleterious effects by enhancing immunologic
recognition of the allograft [39]. Nonspecific injuries
(eg, lung ischemia, gastric content aspiration, etc.)
cause increased production of pro-inflammatorymedi-
ators and upregulation of donor organ HLA. CMV
and other infections also have many potent pro-in-
flammatory effects, including productions of viral-spe-
cific proteins that mimic HLA or act as superantigens
and promiscuously (nonspecifically) activate large pro-
portions of recipient T cells [46,47]. Lung ischemia
and GERD are both common among normal humans,
as well as recipients of other solid organ transplanta-
tions, and does not cause BOS in either population.
CMV pneumonia has also been implicated in chronic
rejection of other transplanted solid organs, but
without concurrent development of BOS [46,48].
Alloantigen Recognition
It has long been known that recognition of alloan-
tigens by recipient T cells is a critical initial step in the
cascade of events leading to chronic allograft rejection
[49]. Solid organ allografts persist indefinitely in T
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donor:recipient MHC disparities. On the other hand,
these same allografts undergo inexorable graft rejec-
tion after adoptive transfers of T cells that are alloge-
neic to the donor organ [32-36]. In addition,
manipulations that result in recipient T cell tolerance
for donor alloantigens obviate BOS [34].
Sequential intrathymic positive and negative selec-
tions limit survival and maturation of nascent thymo-
cytes to only those cells that bear antigen receptors
(TCR) with low avidity for self-HLA-peptide com-
plexes [50]. However, because recipients have not un-
dergone prior negative selection of thymocytes that
are reactive with donor alloantigens, their T cell popu-
lations include unusually high proportions of precursors
with often considerable allo-avidity. Conventional pep-
tide antigens (eg, influenza hemagglutinin epitopes) are
typically recognized by 1 of 10,000-100,000 T cells.
However, the initial precursor frequency for allo-anti-
gen responses is 100 to 1000 times greater [49,50].
Moreover, these responses are also magnified by clonal
proliferations of the allo-antigen reactive T cells
[51,52]. Thus, immune responses to alloantigens are
farmore brisk and intense than those evoked by conven-
tional peptide antigens, which accounts for the difficulty
of allograft rejection prevention (or treatment) by
medical therapies.
Inflammatory Responses to Allografts
Inflammatory infiltrations into experimental allo-
grafts follow a staged, sequential time course. These
animal models include heterotopic tracheal implanta-
tions into mice, orthotopic lung transplantations in
higher species, and recent development of human-mu-
rine chimeras [32-36,53,54]. These models generally
show that recipient T cells are present in the allograft
within a few days, followed by successive waves of mac-
rophages, neutrophils, and lesser numbers of other
leukocytes, including B cells.
Interestingly, T cell numbers, and eventually other
inflammatory cell infiltrations, within the allograft
later tend to diminish, particularly after extensive pro-
gression of airway fibroproliferation. It is not uncom-
mon in both humans and animal models for fully
developed BOS histologic lesions to appear nearly
bereft of inflammatory cells [55].
Diagnosis of BOS after Lung Transplant
The gold standard for diagnosis of BO is demon-
strationof typicalfibroproliferative lesionsonhistologic
evaluations of lung specimens [55]. Transbronchial
biopsies (TBB) obtained by bronchoscopy are often
used as the initial diagnostic procedure. The diagnostic
sensitivity of TBB is notably limited (20%-50%),
however, because of the heterogeneity of BO, and small
biopsy size [38,40,56] Open lung biopsy or video-assisted thorascopic (VAT)procedures are farmore sen-
sitive, but also far more invasive, and are generally
reserved for unusual or confusing diagnostic problems.
Inmost cases, a surrogate diagnosis of BO is established
in lung transplant recipients by spirometric findings of
expiratory airflow obstruction (ie, the term BOS)
[39,56]. Although pulmonary function tests are clini-
cally expedient, the concordance between BOS and
histologically proven BO has not really be established,
and by some indications spirometry has far from perfect
sensitivity and specificity [42].
The biggest problem with physiologic testing,
however, is the inability of these measures to detect
impending or even very early allograft injury. The
development of overt expiratory airflow obstruction
indicates BOS is widespread and advanced. It seems
likely that by the time the airway lesions are detectible
by spirometry, the fibroproliferative abnormality has
already progressed to irreversibility, which probably
accounts for the refractoriness of BOS to medical
treatment.Biomarkers of BOS
The identification of biomarkers that accurately
predict imminent BOS, or detect very early disease at
a stage when the allo-injury may be more amenable
to treatment, could represent a significant advance.
The clinical utilization of assays based on global
markers of immunologic activity or nonspecific lung
injury is usually limited by their inability to distinguish
BOS from infections, acute rejection or, in the case of
single lung transplantations, underlying processes of
the remaining native, diseased lung. No biomarkers
for BOS have yet been validated in large prospective
cohorts.
We have shown in cross-sectional studies that pe-
ripheral T cell clonal expansions, particularly among
CD4 T cells, are unusually frequent and extreme in
lung transplant recipients with BOS. These clonal ex-
pansions were also evident in some patients before they
developed expiratory airflow obstruction [51,52].
We have lately examined surrogate markers of
CD4 T cell clonality, to develop a more facile assay
for monitoring the intensity of chronic allo-rejection
[57]. Nearly all normal human CD4 T-lymphocytes
express the costimulatory molecule CD28 on their
cell surfaces. However, CD28 becomes downregulated
on T cells that have undergone repeated (clonal) divi-
sions, and proportions of CD28null T cells are often in-
creased among patients with chronic adaptive immune
diseases [58]. In addition to loss of cell surface CD28,
the CD41CD28null cells also develop unusual and
potentially pathogenic phenotypes that include
expression of killer immunoglobulin-like receptors
(KIR), autonomous production of inteferon (IFN)-g
and tumor necrosis factor (TNF)-a, as well as
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zyme B, which are otherwise never seen among ‘‘nor-
mal’’ CD4 T cells. We hypothesized CD41CD28null
cells may also be present in the circulation of lung
transplant recipients, especially among those with
particularly intense chronic allograft responses.
The CD41CD28null lymphocytes we found in
lung transplant recipients also had many pathogenic
characteristics, including relative resistance to anti-
proliferative effects of cyclosporine (CsA) [57]. Most
importantly, the presence of increased proportions of
CD41CD28null cells was associated with worse prog-
noses among individual lung transplant recipients,
regardless of their status at the time of the T cell
assays. Thus, CD28 quantitation was able to predict
many of the subsequent clinical deteriorations among
recipients with normal spirometry at the time of test-
ing, as well as identify most of the lung transplant
recipients who were destined for poor outcomes
(Figure 1). Neither acute rejection nor pulmonary
infections confounded these CD28 determinations.
Selected assays of peripheral T cells may provide
insights into the pathogenesis of BOS and/or have
clinical utility to predict imminent allograft injuries.
A longitudinal prospective study of CD28 expression
among a lung transplant recipient cohort is ongoing,
as are investigations using a humanized mouse model
for in vivo generation and characterization of human
CD41CD28null T-cells [53], and further work on
methods to induce specific tolerance to donor
alloantigens [59].CLINICAL ASSESSMENTOF BOS AFTER HCT
Because patients are often asymptomatic in the
early stages of BOS, diagnosis is often delayed until sig-
nificant air flow obstruction has occurred, leading to
dyspnea on exertion and poor exercise tolerance [60].
Other signs and symptoms may include hyperinflationFigure 1. Survival curves showing cumulative freedom from major adverse e
ients stratified by their CD28 expressions. Left panel: major adverse event-free
all recipients (including subjects with either BOS and no evidence of rejection
CD28% low denotes subjects with CD41CD281/CD41Total\0.90. Values for
are 0.98 6 0.02. Tick marks denote interval censored events, and numbers i
subjects that were censored at 24months of observation. Comparisons werem
from major adverse events of CD28% high (n 5 24) and CD28% low (n 5 1
permission.on examination or chest X-ray, crackles, or wheeze
by auscultation, and a nonproductive cough by history.
Both because patientswithBOSare at increased risk for
infections, and because infections may mimic BOS
signs and symptoms, a thorough infectious disease
workup is crucial. Importantly, BOS patients should
be distinguished from those with cryptogenic organiz-
ing pneumonia (COP), also known as bronchiolitis
obliterans organizing pneumonia (BOOP). COP typi-
cally presents with fever, productive cough, consoli-
dated infiltrates on chest CT, and has an excellent
response rate to steroid therapy. In contrast, BOS
is rarely associated with fever and infiltrates and is
often progressive despite immunosuppressive modula-
tions. Thus, the initial workup for a patient with
new onset air flow obstruction should include:
pulmonary function tests (PFTs), inspiratory and
high resolution expiratory chest CT, and comprehen-
sive infectious disease evaluation (including bronchoal-
veolar lavage (BAL) with stains and cultures for viral,
bacterial, fungal, and mycobacterial pathogens, blood
cultures, CMV polymerase chain reaction [PCR], and
nasopharyngeal wash for respiratory viruses), and
a thorough cGVHD evaluation. We also recommend
an echocardiogram to assess pulmonary artery pres-
sures and a 6-minute walk evaluation for oxygenation
status in patients with likely BOS. For patients
diagnosed with infections, a follow-up pulmonary
evaluation should be done after resolution to evaluate
for BOS.
The early diagnosis of BOS remains a challenge;
this probably contributes to the poor prognosis of
this disease because optimal therapies are likely to be
most effective in the earliest stages of disease. By pul-
monary function test, FEV1 is the most sensitive
marker of emerging obstructive disease and severity
of BOS [1] (Figure 2). Thus, FEV1 decline in a given
patient post-HCT is likely the best way to identify pa-
tients at risk to develop significant BOS disease [7], us-
ing an annualized decline in FEV1 of .5%/year withvents (death or necessity for retransplantation) of lung transplant recip-
survival (EFS) of CD28% high (n5 46) and CD28% low (n5 19) among
). CD28% high denotes subjects with CD41CD281/CD41Total $0.90.
CD28% among nontransplanted healthy, age-matched normal individuals
n parenthesis at end of the survival curves denote remaining, unafflicted
ade by log-rank. Right panel: survival curves showing cumulative freedom
6) among the recipients with BOS. Reprinted from reference [57] with
Figure 2. Diagram of spirogram and flow volume curves representative of patients with bronchiolitis obliterans syndrome [70].
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tential for progression to BOS. Frequent monitoring
of PFTs in the post-HCT period may ultimately
improve diagnosis of patients in early stages of BOS,
although this has yet to be tested and would commend
monetary considerations.
Recently, the National Institutes of Health (NIH)
cGVHD consensus project developed a definition of
BOS [3] (Table 1) in an effort to standardize definitions,
thereby enhancing comparisons among publications on
cGVHDmanifestationsbetween trial centers.This def-
inition required demonstration of the characteristic
findings of airflow obstruction by: (1) decreased FEV1
(FEV1\75%predicted), and (2) evidence of airwayob-
struction with FEV1/FVC\0.7, and air trapping: (3)
elevated residual volume of air (RV .120%), and (4)
air trapping on expiratory CT or lung biopsy[3], with
lung biopsy or (5) another manifestation of cGVHD
[3]. Retrospective evaluation of a cohort of BOS pa-
tients at NIHwith clinically identified (n5 15) or clin-
ically identified with biopsy proven disease (n 5 7)
revealed only 18% (4/22) of patients met theNIH con-
sensus definition for a clinical diagnosis of BOS, all ofTable 1. NIH Consensus BOS Definition and Proposed
Modification
NIH Consensus BOS
Clinical Definition
Proposed Amended NIH
BOS Clinical Definition
Absence of infection Absence of infection
Another cGVHD manifestation Another cGVHD manifestation
FEV1 < 75% predicted FEV1 < 75% predicted OR decline >10%
FEV1/FVC <0.7 (ratio) Sign of obstruction:
FEV1/SVC <0.7 (ratio)
OR RV OR RV/TLC > 120%
AND CT: air trapping
RV >120%
CT: air trapping or
bronchiectasis
cGVHD indicates chronic graft-versus-host disease; RV, residual volume;
SVC, slow vital capacity; TLC, total lung capacity; BOS, bronchiolitis ob-
literans syndrome; NIH, National Institutes of Health; FEV1, 1-second
forced expiratory volume; CT, computed tomography.which had an FEV1# 55% suggestive of severe disease.
This low capture rate highlighted the need for thought-
ful evaluation of diagnostic approaches to BOS.
Although lung biopsy is definitive for diagnosis, the
complication rate of 13% (including persistent air leak
and death) has diminished enthusiasm for this approach
[61-64]. Review of the literature suggested that patients
may have falsely elevated ratios of FEV1/FVC because
of dynamic airway obstruction (early collapse of airways
during forced expiration) and that slow vital capacity
(SVC) may better reflect the true vital capacity and
reveal ‘‘hidden’’ obstruction in most BOS patients. De-
spite this, there was evidence that patients withmyositis
or manifestations of GVHD similar to scleroderma
might still evade detection because of external restric-
tion of air movement. This decrease in excursion could
further reduce the vital capacity, masking obstructive
disease [65,66]. The ratio of elevated residual volume
over total lung capacity (RV/TLC) could be used to re-
veal air trapping in thesepatients similar topatientswith
scleroderma and obstructive lung disease [67,68]. In
combinationwithCTevidenceof air trapping, a specific
finding of BOS [69], these parameters may be able to
identify patients with early obstruction even in the pres-
ence of severe restrictive diseases ofmyositis or sclerotic
GVHD. In a recent publication, we proposed that these
criteria be modified to capture patients with earlier dis-
ease for interventionswithminimal risk, reservingmore
stringent criteria for diagnosis and therapies with
greater risks (Table 1) [70]. Further studies will be
needed to refine these criteria to enhance sensitivity
and specificity for this diagnosis.
Treatment of BOS
The prognosis for BOS is poor, with an overall sur-
vival (OS) rate of 44% at 2 years and 13% at 5 years
[1,7,71,72]. Despite advances in immunosuppressive
S112 Biol Blood Marrow Transplant 16:S106-S114, 2010J. W. Chien et al.regimens and supportive care, these dismal outcomes
are unchanged between reports from the earliest and
recent publications on BOS after HCT: 1989 to 2003
[1,60]. Nonetheless, because of the presumed
alloimmune pathogenesis of disease, immunosuppres-
sive agents still comprise the backbone of BOS
treatment including: calcineurin inhibitors, sirolimus,
corticosteroids, azathioprine, and antithymocyte
globulin (ATG). Data from lung transplantation litera-
ture suggests that these agents are likely to be beneficial
by decreasing the rate of progression of BOS [73,74].
Current recommendations for BOS therapy include:
high-dose systemic corticosteroids (1 mg/kg/day) for
a protracted course with expected ‘‘improvements’’ in
8% to 20%, of which most are likely transient given
the poor overall survival [1,75-77]. Azithromycin and
inhaled steroids have been tested in small clinical trials
of patients with BOS afterHCTwith evidence for some
benefit by pulmonary function tests [78,79]. Anecdotal
reports of efficacy for the stabilization of BOS include:
extracorporeal photopheresis (6/7 patients stable
disease), TNFblockade (1/1 patient stable disease), im-
atinib (1/1 patient improved) [75,80-83]. Finally, novel
agents such as leukotriene inhibitors and statins have
emerged as possible therapies [84,85]. Human andmu-
rine studies have demonstrated high levels of leukotri-
enes with BOS after lung transplant and pulmonary
fibrosis [86-88] and a pilot study with montelukast (a
leukotriene inhibitor) showed benefit in 3 of 5 patients
with BOS after HCT [85].
In addition to immunosuppressive therapies,
supportive care is critical for this very ill population.
Hypoxia with exertion may be missed with spot check
saturations in a waiting room after rest; saturation after
a 6-minute walk will reveal the necessity of supplemen-
tal oxygen. Consideration of contributing factors to
poorer pulmonary status should include: methemoglo-
binemia (PJP prophylaxis agents), beta-blockers (vaso-
constriction), and ACE-inhibitors (cough). Most
importantly, investigation should be frequent for active
and potential pulmonary infections in patients with
BOS. Of the 34 cases of BOS reported after death,
50% succumbed to infectious complications rather
than pulmonary progression [1,66]. Risk factors are
likely to include immunosuppression (especially pro-
tracted steroid therapy), severity of disease, and other
complicating factors that occur with cGVHD, such as
aspiration, poor nutrition, and lymphopenia.
Given the poor prognosis of BOS afterHSCT, clin-
ical trials are currently underway to test novel therapies
including: montelukast (NCI and FHCRC, Seattle) and
Symbicort (Paris). A U54 grant by the Office of Rare
Diseasewas recently funded todevelop trials forBOSaf-
ter HSCT. Outcomes from these trials and future stud-
ies will hopefully provide insight into themechanisms of
this rare complication ofHSCTandprovide avenues for
better identification of patients at risk for BOS disease,those who have developed early disease, andwhich ther-
apies are most likely to benefit these patients, to ulti-
mately improve survival and quality of life.ACKNOWLEDGMENTS
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